A sub-analysis of 47 patients within the phase II LUNG-MAP study, evaluating talazoparib (PARP inhibitor) and avelumab (anti-PD-L1) in advanced non-squamous NSCLC with pathogenic STK11 genomic alterations did not meet pre-specified efficacy thresholds (ORR 2%). This evidence concerns the gene CD274 and non-small cell lung carcinoma.